| Isotype | IgG |
| ProductType | BlockingPeptide |
| Units | 50µg |
| Host | Rabbit |
| Speciesreactivity | Human |
| Application | WesternBlotting |
BackgroundMutationsinelongationofverylong-chainfattyacid-4(ELOVL4)areassociatedwithautosomaldominantStargardt-likemaculardegeneration(STGD3),withafivebase-pair(5bp)deletionmutationresultinginthelossof51carboxy-terminalaminoacidsandtruncationoftheprotein.Elovl4isexpressedintheretinaandonlyalimitednumberofmammalianothertissues,includingskin,withunknownfunction.Inamousemodelwiththe5-bpdeletionintheElovl4gene,miceintheheterozygousstate(Elovl4(+/del))demonstrateprogressivephotoreceptordegeneration.Homozygousmice(Elovl4(del/del))displayscaly,wrinkledskin,haveseverelycompromisedepidermalpermeABIlitybarrierfunction,anddiewithinafewhoursafterbirth.LipidanalysesofepidermisfromElovl4(del/del)miceshowadecreaseinverylong-chainfattyacids(VLFAs)inboththeceramide/glucosylceramideandthefreefatty-acidfractions.ELOVL4isrequiredforgeneratingVLFAcriticalforepidermalbarrierfunction.
Synonyms:Elongationofverylongchainfattyacidsprotein4,ELOV4
Source
Immunogen:SyntheticpeptdidederivedfromthehumanELOV4protein
Product
ProductForm:Unconjugated
Formulation:Providedassolutioninphosphatebufferedsalinewith0.08%sodiumazide
Concentration:Seevialforconcentration
ApplicationsForusewithELOV4polyclonalantibodies(Cat.No.X2087P&X2381P).
FunctionalAnalysis:WesternBlotting
PositiveControl:Expressedintheretinaandatmuchlowerlevelinthebrain.
StorageProductshouldbestoredat-20ºC.Aliquottoavoidfreeze/thawcycles
ProductStability:Productsarestableforoneyearfrompurchasewhenstoredproperly
ShippingConditions:Shipongelice,storeat-20ºCimmediatelyuponarrival
CautionThisproductisintendedFORRESEARCHUSEONLY,andFORTESTSINVITRO,notforuseindiagnosticortherapeuticproceduresinvolvinghumansoranimals.Itmaycontainhazardousingredients. PleaserefertotheSafetyDataSheets(SDS)foradditionalinformationandproperhandlingprocedures.Disposeproductremaindersaccordingtolocalregulations.Thisdatasheetisasaccurateasreasonablyachievable,butNordic-Mubioacceptsnoliabilityforanyinaccuraciesoromissionsinthisinformation.
References1:KobayashiT,etal.ELOVL2overexpressionenhancestriacylglycerolsynthesisin3T3-L1andF442Acells.FEBSLett.2007Jul10;581(17):3157-63.Epub2007Jun11.2:DeAngelisMM,etal.Cigarettesmoking,CFH,APOE,ELOVL4,andriskofneovascularage-relatedmaculardegeneration.ArchOphthalmol.2007Jan;125(1):49-54.3:VasireddyV,etal.LossoffunctionalELOVL4depletesverylong-chainfattyacids(>or=C28)andtheuniqueomega-O-acylceramidesinskinleADIngtoneonataldeath.HumMolGenet.2007Mar1;16(5):471-82.Epub2007Jan5.4:SridharanS,etal.X-raycrystalstructureofMycobacteriumtuberculosisbeta-ketoacylacylcarrierproteinsynthaseII(mtKasB).JMolBiol.2007Feb16;366(2):469-80.Epub2006Nov7.5:SeitsonenS,etal.AnalysisofvariantsinthecomplementfactorH,theelongationofverylongchainfattyacids-like4andthehemicentin1genesofage-relatedmaculardegenerationintheFinnishpopulation.MolVis.2006Jul20;12:796-801.6:JakobssonA,etal.Fattyacidelongasesinmammals:theirregulationandrolesinmetabolism.ProgLipidRes.2006May;45(3):237-49.Epub2006Mar6.Review.7:PleiteR,etal.Inhibitorsoffattyacidbiosynthesisinsunflowerseeds.JPlantPhysiol.2006Sep;163(9):885-94.Epub2006Feb28.8:KajikawaM,etal.Isolationandfunctionalcharacterizationoffattyaciddelta5-elongasegenefromtheliverwortMarchantiapolymorphaL.FEBSLett.2006Jan9;580(1):149-54.Epub2005Dec6.9:KooAJ,etal.Identificationofaplastidacyl-acylcarrierproteinsynthetaseinArabidopsisanditsroleintheactivationandelongationofexogenousfattyacids.PlantJ.2005Nov;44(4):620-32.10:ZhangK.,etal.A5-bpdeletioninELOVL4isassociatedwithtworelatedformsofautosomaldominantmaculardystrophy.;Nat.Genet.27:89-93(2001).11:EdwardsA.O.,etal;AnovelgeneforautosomaldominantStargardt-likemaculardystrophywithhomologytotheSUR4proteinfamily.;Invest.Ophthalmol.Vis.Sci.42:2652-2663(2001).
ProteinReference(s)
DatabaseName:UniProt
Accessionnumber:Q9GZR5(Human)
SpeciesAccession:Human
SafetyDatasheet(s)forthisproduct:NM_SodiumAzide/wp-content/uploads/SDS/AntibodySDSwithSodiumAzideNoridic-MUbio.pdf
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
多抗，稀释度更大，特异性相对较差，容易出现多条带。
兔的单克隆抗体和鼠的单克隆抗体在使用上不会有什么区别。
用来很多抗体，许多时候觉得单抗多抗也未必是理论上那样的。单抗做不好的也有，多抗条带唯一且清晰的也有。
而且很多蛋白的抗体未必有那么多的选择。
抗原有两个基本特性，即抗原性和免疫原性。有抗原性的物质不一定有免疫原性，所以由此引出半抗原和完全全抗原，半抗原必须经过经过一定的改造（偶联蛋白载体BSA，OVA或者HSA等大分子物质）方能成为完全。一般而言完全抗原分子量越大（大于10KDa），结构越复杂引起免疫反应的能力也就越强。
抗体就是能与特异性抗原结合的免疫球蛋白，抗体一般分为多克隆抗体和单克隆抗体，多克隆抗体能与抗原的多个表位结合。本篇主要讲述兔来源的多克隆抗体的生产步骤
多抗一般制备流程：完全抗原的准备→兔子的免疫→ 效价检测和终放→抗体亲和纯化→抗体的浓缩和保存。
一般来说多克隆的阳性率高一些，但出现假阳性的比例也高一些。
抗体的特异性鉴定 抗体的特异性是指与相应抗原或近似抗原物质的识别能力。抗体的特异性高，它的识别能力就强。衡量特异性通常以交叉反应率来表示。交叉反应率可用竞争抑制试验测定。以不同浓度抗原和近似抗原分别做竞争抑制曲线，计算各自的结合率，求出各自在 IC50时的浓度，并按下列公式计算交叉反应率。 如果所用抗原浓度IC50浓度为pg/管，而一些近似抗原物质的IC50浓度几乎是无穷大时，表示 这一抗血清与其他抗原物质的交叉反应率近似为 0，即该血清的特异性较好。
抗体的亲和力 是指抗体和抗原结合的牢固程度。亲和力的高低是由抗原分子的大小、抗体分子的结合位点与抗原决定簇之间立体构型的合适度决定的。有助于维持抗原抗体复合物稳定的分子间力有氢键、疏水键、侧链相反电荷基因的库仑力、范德华力和空间斥力。亲和力常以亲和常数K表示，K的单位是L/mol，通常K的范围在 108 ～1010 /mol，也有多达 1014 /mol。抗体亲和力的测定对抗体的筛选，确定抗体的用途，验证抗体的均一性等均有重要意义。向左转|向右转
